GlySure, Ltd., has developed a continuous intravascular glucose monitoring system to meet the $5B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the Hospital Intensive Care Unit (ICU). Hospital TGC has been shown in prospective outcomes trials to produce significant improvement in patient outcomes including 46% reduction in incidence of sepsis, 41% reduction in renal failure, and 34% reduction in mortality. The challenge for hospitals is that using insulin to tightly control blood glucose increases the risk of hypoglycemia which has itself been associated with increased mortality. To safely implement TGC requires near hourly sampling of blood glucose levels to ensure the patient stays in the target range - a time and resource requirement that most hospitals cannot meet. In a recent editorial in Critical Care, James Krinsley summed up the need for hospital CGM as follows, "Successful management of all three domains of glycemic control will require the use of continuous or nearly continuous technologies. Fortunately, this era is about to begin." GlySure has demonstrated through clinical testing on over 200 ICU patients, highly accurate sensors and systems. The company has recently received ISO 13485 certification and completed enrollment in a CE regulatory trial on cardiac surgery patients showing accurate monitoring throughout the length of stay in ICU.
Type
Private
HQ
Abingdon, GB
Founded
2006
Employees
27 (est)
GlySure was founded in 2006 and is headquartered in Abingdon, GB

GlySure Locations

Abingdon, GB

GlySure Metrics

GlySure Summary

Founding Date

2006

Total Funding

$24.4 M

Latest funding size

$13.6 M

Time since last funding

about 4 years

Investors

GlySure's latest funding round of $13.6 M was in November 2012. In total, GlySure has raised $24.4 M.
11% of current employees of GlySure are female and 89% are male.

GlySure Online Presence

GlySure Company Life

You may also be interested in